The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as second-line therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.
 
Zixun Yan
No Relationships to Disclose
 
Yongxian Hu
No Relationships to Disclose
 
Lingshuang Sheng
No Relationships to Disclose
 
Li Wang
No Relationships to Disclose
 
Shu Cheng
No Relationships to Disclose
 
Wen Wu
No Relationships to Disclose
 
Pengpeng Xu
No Relationships to Disclose
 
Muchen Zhang
No Relationships to Disclose
 
Chris Wang
No Relationships to Disclose
 
Zisong Zhou
No Relationships to Disclose
 
Su Yang
No Relationships to Disclose
 
Yun Qin
No Relationships to Disclose
 
He Huang
No Relationships to Disclose
 
Weili Zhao
No Relationships to Disclose